A comprehensive study of the genetics of a common lung cancer finds that more than half the tumors have mutations that might be treated by drugs that are already in the pipeline or that could be developed.
By GINA KOLATA, New York Times
Sun, 09/09/2012 - 10:11am
A comprehensive study of the genetics of a common lung cancer finds that more than half the tumors have mutations that might be treated by drugs that are already in the pipeline or that could be developed.